Veradermics (MANE) priced 15.08M shares at $17.00. The deal size was increased from 13.35M and priced above the $14.00-$16.00 range. Jefferies, Leerink, Citi and Cantor Fitzgerald are acting as joint book running managers for the offering. Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing therapeutics for common aesthetic and dermatological conditions. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MANE: